BRIEF

on Theranexus (EPA:ALTHX)

Theranexus and BBDF Announce Positive Results for Batten-1 Phase 1/2 Study

Stock price chart of Theranexus (EPA:ALTHX) showing fluctuations.

Theranexus company in collaboration with the Beyond Batten Disease Foundation (BBDF) revealed the final results of the phase 1/2 study of the drug Batten-1, treating the juvenile form of Batten disease (CLN3). The data, after 18 months of treatment, show a significant stabilization of motor symptoms in the six young adult participants.

In these patients, the mean score on the modified UBDRS scale, a measure of motor symptoms, showed very limited progression compared to a control study, suggesting significant effectiveness of the treatment. Theranexus CEO Mathieu Charvériat highlighted the encouragement that these results represent for patients and their families, and discussed the upcoming launch of a phase 3 trial, already approved by the FDA and EMA.

R. P.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Theranexus news